Jennison Associates’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $73M | Sell |
|
|||||
|
2025
Q2 | $71.8M | Sell |
|
|||||
|
2025
Q1 | $89M | Sell |
|
|||||
|
2024
Q4 | $112M | Buy |
|
|||||
|
2024
Q3 | $38.6M | Sell |
|
|||||
|
2024
Q2 | $68.7M | Buy |
|
|||||
|
2024
Q1 | $47.6M | Sell |
|
|||||
|
2023
Q4 | $59.5M | Buy |
|
|||||
|
2023
Q3 | $46.1M | Buy |
|
|||||
|
2023
Q2 | $20.8M | Sell |
|
|||||
|
2023
Q1 | $22.9M | Buy |
|
|||||
|
2022
Q4 | $26.2M | Buy |
|
|||||
|
2022
Q3 | $15M | Buy |
|
|||||
|
2022
Q2 | $13.6M | Buy |
|
|||||
|
2020
Q3 | – | Sell |
|
|||||
|
2020
Q2 | $41.7M | Sell |
|
|||||
|
2020
Q1 | $33.1M | Buy |
|
|||||
|
2019
Q4 | $26.6M | Buy |
|
|||||
|
2019
Q3 | $21M | Sell |
|
|||||
|
2019
Q2 | $41.5M | Buy |
|
|||||
|
2019
Q1 | $36M | Sell |
|
|||||
|
2018
Q4 | $30.4M | Buy |
|
|||||
|
2018
Q3 | $49.7M | Buy |
|
|||||
|
2018
Q2 | $39.3M | Buy |
|
|||||
|
2018
Q1 | $32.6M | Buy |
|
|||||
|
2017
Q4 | $25.3M | Buy |
|
|||||
|
2017
Q3 | $19.7M | Sell |
|
|||||
|
2017
Q2 | $14.8M | Sell |
|
|||||
|
2017
Q1 | $28.2M | Buy |
|
|||||
|
2016
Q4 | $14.3M | Buy |
|
|||||
|
2016
Q3 | $18.6M | Sell |
|
|||||
|
2016
Q2 | $16.8M | Sell |
|
|||||
|
2016
Q1 | $14.6M | Sell |
|
|||||
|
2015
Q4 | $28M | Sell |
|
|||||
|
2015
Q3 | $34.7M | Sell |
|
|||||
|
2015
Q2 | $41.8M | Buy |
|
|||||
|
2015
Q1 | $34.5M | Sell |
|
|||||
|
2014
Q4 | $19.7M | Buy |
|
|||||
|
2013
Q4 | – | Sell |
|
|||||
|
2013
Q3 | $18.6M | Sell |
|
|||||
|
2013
Q2 | $22.1M | Buy |
|